Caroline Gahm

Caroline Gahm

Auto-generated profile, based on publicly available information

Caroline Gahm

Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences Intervention and Technology, Karolinska Institutet, Stockholm, Sweden; Department of Head Neck, Lung and Skin Cancer, Karolinska University Hospital, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2023 in Journal of Pediatric Surgery
Verified
Journal Article
Open access
AHAnders Holmquist
Anders Holmquist
MWMalin Wendt
Malin Wendt
GPGeorgios Papatziamos
Georgios Papatziamos
JSJan Svensson
Jan Svensson
TWTomas Wester
Tomas Wester
CGCaroline Gahm
Caroline Gahm
Recurrent tracheoesophageal fistula (rTEF) is a well-known complication after surgery of EA, occurring in roughly 3-10% of the patients. Recent studies have highlighted safety and efficacy of endoscopic management of recurrent TEF. The aim of this study was to evaluate the efficacy of chemocauterization with trichloroacetic acid (TCA) in rTEF and congenital tracheoesophageal fistula (cTEF). Retrospective chart review of consecutive patients with recurrent or congenital TEF who underwent endoscopic chemo-cauterization between 2018 and 2022 at a tertiary center. Children diagnosed with TEF who underwent primary or secondary endoscopic treatment were included. Median follow up time was 19 months for rTEF and 33 months for cTEF. During the study period, 18 patients were treated endoscopically by chemocatuerization with TCA at our institution. Treatment of recurrent TEF was successful in 13 of 14 patients (93%) Treatment of congenital TEF was successful in 2 of 4 patients (50%). In 14 patients, closure was seen after 1-2 treatments. There were no serious adverse reactions or complications to the endoscopic treatment of TEF. Endoscopic chemocauterization is a minimal invasive technique with low morbidity and high success rate and may be considered as primary treatment for recurrent TEF. III.

12 December 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
MSMarit J B van Stigt
Marit J B van Stigt
AHAnne-Fleur R L van Hal
Anne-Fleur R L van Hal
ABArnold J N Bittermann
Arnold J N Bittermann
CBColin R Butler
Colin R Butler
ICIlse Ceelie
Ilse Ceelie
MLMaud Lindeboom
Maud Lindeboom
Introduction Tracheomalacia (TM) often occurs in children with oesophageal atresia (OA), leading to recurrent respiratory symptoms and in severe cases to blue spells or ultimately respiratory arrest. In some patients, a secondary posterior tracheopexy may then be indicated. This secondary surgery, as well as respiratory morbidity, may be prevented by performing a primary posterior tracheopexy (PPT) concurrent with primary OA correction. The aim of this trial is to determine if a PPT can decrease—or prevent—tracheal collapse in newborns with OA and TM. Additionally, the trial aims to determine whether the potential observed effect of PPT on tracheal stability is sustained over time. Methods and analysis This is an international multicentre double-blind randomised controlled trial. Seventy-eight children with OA type C will be randomised 1:1 into the no-PPT group or PPT group. Randomisation will be stratified by centre. The degree and location of TM are assessed during preoperative, intraoperative and two postoperative tracheobronchoscopies. The occurrence of TM will be evaluated during three routine follow-up consultations until the age of 6 months. The primary outcome is the degree of collapse of the tracheal wall during the intraoperative tracheobronchoscopy (after performing the PPT/no-PPT), measured in percentages. The difference in the mean degree of collapse will be compared between the no-PPT and the PPT groups using linear regression, adjusting for centre and the preoperative degree of tracheal collapse at baseline. The adjusted mean difference will be reported as effect size together with its 95% CI. Ethics and dissemination Patients will be included after written parental informed consent. The risks and burden associated with the trial are minimal. The institutional review board of the University Medical Center Utrecht has approved this protocol (METC-number 23-256/A). Results will be shared in a peer-reviewed scientific journal and presented at international conferences. Trial registration number NCT06335862.

30 September 2023 in Cancer Medicine
Verified
Journal Article
Open access
LHLalle Hammarstedt-Nordenvall
Lalle Hammarstedt-Nordenvall
RBRusana Bark
Rusana Bark
AEAlexandra Elliot
Alexandra Elliot
MBMathias Von Beckerath
Mathias Von Beckerath
CGCaroline Gahm
Caroline Gahm
Background: Optimum management of the N0 neck is unresolved in parotid salivary gland cancer. Sentinel node biopsy (SNB) can reliably detect microscopic lymph node metastasis and its´ clinical use is increasing for head and neck tumors. The object of this study was to establish whether the technique is applicable to detect distribution of sentinel nodes for parotid tumors.Materials and Methods: Prosepective observational study in 30 patients with benign or low‐grade T1‐T2N0 malignant tumors in the parotid gland planned for surgical treatment. Distribution of SN was detected with a preoperative ultrasound‐guided peritumoral injection with a technetium‐99 (Tc‐99 m) laballed tracer followed by a SPECT–CT and intraoperative measurement in the neck and parotidal tissue. In patients with cytologically suspected malignant tumor or highly unclerar cytology, SNB was also performed.Results: Sentinel nodes (SNs) were detected in 26/30 cases. Out of these, 7 presented with only one SN, whereas multiple sentinel nodes where detected in 19 cases. No SNs were found in neck level 1. SN was detected in level 5 independent of tumor location within the parotid gland. An intraparotidal distribution of SNs was more frequent in larger tumors.Conclusions: The use of SN‐technique in the planning of surgical treatment of parotid tumors seems feasible. It may be of clinical value for patients with parotid cancer to enable a more accurate staging and to detect occult metastasis in the SNs within the parotid as well as in the neck, enabaling the possibility to surgically remove all positive SNs at primary surgery and with reduced surgical morbidity.

17 June 2023 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Open access
GMGabriel Medin
Gabriel Medin
MWMalin Wendt
Malin Wendt
AEAndreas Ekborn
Andreas Ekborn
AAAndreas Andersson
Andreas Andersson
CGCaroline Gahm
Caroline Gahm
Supraglottoplasty (SGP) for severe laryngomalacia (LM) in children with medical comorbidities has been associated with high risk of surgical failure and increased need of postoperative pediatric intensive care unit (PICU) intervention, but evidence for this is ambiguous. The objective was to evaluate surgical outcome and risk of need for PICU-intervention following SGP for severe LM in comorbid patients. Retrospective observational study of 116 patients treated with SGP for severe LM between 2000 and 2021 at a tertial referral pediatric airway surgery center Karolinska University Hospital. Medical records were reviewed and patient data regarding surgical timing, type of SGP procedure, PICU-intervention, complications, and outcomes were recorded. Patients were defined as non-comorbid vs high-risk comorbid (HRC) based on a coexisting comorbidity for risk of surgical failure and postoperative PICU-intervention. Surgical failure was defined as need of revision surgery, tracheostomy or assisted ventilation (continuous positive airway pressure and bilevel positive airway pressure). PICU intervention was defined as need of postoperative assisted ventilation or intubation. Statistical comparisons were performed with outcome of SGP on children with LM and no comorbidities. 41/116 patients included had a HRC associated with an increased risk of PICU-intervention and surgical failure. 75/116 patients were defined as non-comorbid. The overall surgical success in the study population was 89.7% (104/116), 94.7% in the non HRC group vs 80.5% in the HRC-group. 5/41 HRC patients and 1/75 non-comorbid patients needed SGP revision in which 5/6 was successful. There was no significantly increased need for postoperative PICU intervention in HRC patients. SGP for severe LM patients with high-risk comorbidities performed in a tertiary setting had an overall good result and low risk of PICU-intervention. Revision SGP was more common in HRC patients but had a good outcome. Multidisciplinary experience in perioperative care of comorbid patients may be of key importance for outcome and children with high-risk comorbidities should thus not be withheld the possible benefit of SGP without assessment at a tertiary pediatric airway center.


6 March 2026 in Cancer Reports
Verified
Journal Article
Open access
PDF file
MJMarcus Jansson
Marcus Jansson
RBRusana Bark
Rusana Bark
AEAlexandra Elliot
Alexandra Elliot
LHLalle Hammarstedt-Nordenvall
Lalle Hammarstedt-Nordenvall
CGCaroline Gahm
Caroline Gahm
Background: Salivary gland carcinomas are rare and heterogeneous malignancies, more common in the parotid gland but also in submandibular and minor salivary glands. Surgery, often combined with radiotherapy, is the main treatment. Management of the clinically node‐negative (cN0) neck is debated, with some favoring extensive surgery and others active surveillance. The sentinel node (SN) technique may improve nodal staging and personalized surgery but is understudied in non‐parotid tumors. Aims: This study aimed to evaluate whether the technique is applicable to assess SN distribution in these patients. Methods and Results: In this prospective observational feasibility study, 40 patients with cytologically suspected benign or malignant non‐parotid salivary gland tumors were enrolled. Preoperatively, patients received an ultrasound‐guided intratumoral injection of Tc‐99m‐labeled tracer, followed by SPECT–CT imaging for SN localization. Intraoperatively, SNs were detected using a gamma probe, and sentinel lymph node biopsy (SLNB) was performed when indicated. SNs were detected in 33 of 39 (85%) patients. Bilateral distribution of SNs was seen in two of 12 patients with minor salivary gland tumors but in none with submandibular tumors ( n = 27). One patient was excluded due to a non‐salivary gland diagnosis. SLNB was performed in 16 patients with cytology indicating aggressive malignancies in which micrometastases were detected in three patients with submandibular gland tumors and in two patients with minor salivary gland tumors. Conclusion: SN mapping was feasible in patients with non‐parotid salivary gland tumors, with a high detection rate using SPECT–CT. SN distribution was primarily ipsilateral but bilateral in two patients with minor salivary gland tumors. Identification of SN micrometastases highlights the potential of SLNB to improve staging accuracy. Our findings support further investigation of the SN technique as a diagnostic tool in the management of cN0 neck in this rare tumor group.